Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

CHRISTINE THAI

Allopathic & Osteopathic Physicians Internal Medicine Rheumatology

NPI
1043224587
CMS profile
1470
Location
HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$874.35

56 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $874.35 56

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

CHRISTINE THAI

NPI 1043224587 · CMS profile ID 1470

Allopathic & Osteopathic Physicians / Internal Medicine / Rheumatology

HUNTINGTON BEACH, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
CHRISTINE THAI, NPI 1043224587, CMS profile ID 1470, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 2; records 1–50 of 56 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1043224587?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

56 matching records · $874.35 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 56 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–50 of 56.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $11.4912/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432525 CMS
Novartis Pharmaceuticals Corporation $16.4712/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415635 CMS
Amgen Inc. $10.2812/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432523 CMS
ABBVIE INC. $9.4612/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515801 CMS
Amgen Inc. $5.0312/01/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432477 CMS
Novartis Pharmaceuticals Corporation $16.5611/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415633 CMS
Amgen Inc. $8.8711/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432521 CMS
Amgen Inc. $21.1811/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432495 CMS
ABBVIE INC. $18.7310/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515797 CMS
UCB, Inc. $18.0710/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 965190347 CMS
Organon LLC $8.1710/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232155 CMS
Amgen Inc. $23.4310/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432519 CMS
Novartis Pharmaceuticals Corporation $16.2610/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415631 CMS
Amgen Inc. $11.8909/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432493 CMS
Amgen Inc. $11.0309/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432517 CMS
Novartis Pharmaceuticals Corporation $13.5109/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415629 CMS
ABBVIE INC. $8.4009/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515793 CMS
Amgen Inc. $15.3409/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432515 CMS
ABBVIE INC. $7.2709/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515789 CMS
Amgen Inc. $7.3109/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432491 CMS
Novartis Pharmaceuticals Corporation $19.4008/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415627 CMS
Amgen Inc. $6.7508/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432489 CMS
Amgen Inc. $18.7507/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432487 CMS
Amgen Inc. $14.3907/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432513 CMS
Novartis Pharmaceuticals Corporation $15.5207/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415625 CMS
Amgen Inc. $27.3207/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432511 CMS
Organon LLC $7.2507/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232141 CMS
ABBVIE INC. $4.4007/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515787 CMS
ABBVIE INC. $10.6806/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515783 CMS
Amgen Inc. $12.7306/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432503 CMS
GlaxoSmithKline, LLC. $18.0206/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 945127825 CMS
Amgen Inc. $4.2805/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432501 CMS
Novartis Pharmaceuticals Corporation $17.6205/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415623 CMS
ABBVIE INC. $28.3205/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515779 CMS
Amgen Inc. $7.7405/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432499 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $14.4805/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887373407 CMS
Amgen Inc. $5.0905/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432479 CMS
ABBVIE INC. $12.7704/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515775 CMS
Novartis Pharmaceuticals Corporation $21.5904/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415621 CMS
ABBVIE INC. $7.6604/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515771 CMS
Amgen Inc. $9.2304/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432509 CMS
ABBVIE INC. $11.6003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515765 CMS
ABBVIE INC. $125.0003/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 892515769 CMS
Amgen Inc. $7.1603/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432485 CMS
Novartis Pharmaceuticals Corporation $15.7003/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894415619 CMS
Aurinia Pharma U.S., Inc. $29.0003/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954105767 CMS
Amgen Inc. $22.7803/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432483 CMS
Amgen Inc. $4.1503/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432507 CMS
Organon LLC $6.1403/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 1022232149 CMS
Amgen Inc. $4.6102/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939432481 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $2,357.35 137
PY2020 $1,472.25 78
PY2021 $298.93 19
PY2022 $874.35 56
PY2023 $974.73 69
PY2024 $693.01 43
PY2025 $811.99 35

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $1,372,053.89 61
PY2024 Recipient $8,444.46 4
PY2024 Principal investigator $1,430,507.12 79
PY2023 Recipient $8,498.49 1
PY2023 Principal investigator $1,858,436.22 86
PY2022 Recipient $72,841.00 2
PY2022 Principal investigator $1,860,641.35 160
PY2021 Recipient $2,012.04 2
PY2021 Principal investigator $577,779.35 91
PY2020 Recipient $2,580.07 2
PY2020 Principal investigator $908,629.40 110
PY2019 Recipient $16,824.73 4
PY2019 Principal investigator $518,505.93 90

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

61 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $2,250.00 12/23/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202531718
Principal investigator 1 ABBVIE INC. $9,482.55 12/23/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202531720
Principal investigator 1 ABBVIE INC. $9,696.18 12/23/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202531734
Principal investigator 1 ABBVIE INC. $240.45 12/23/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202531736
Principal investigator 1 Janssen Research & Development, LLC $1,014.00 12/22/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353057
Principal investigator 1 ABBVIE INC. $11,719.20 12/04/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202527112
Principal investigator 1 ABBVIE INC. $7,026.15 11/05/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202521543
Principal investigator 1 Eli Lilly and Company $19,100.00 11/03/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL (ATTAIN-OA PAIN) ; J2A-MC-GZT1 ; J2A-MC-GZT2 No dispute reported 06/30/2026 1187878309
Principal investigator 1 ABBVIE INC. $2,115.00 10/09/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202514177
Principal investigator 1 Janssen Research & Development, LLC $2,163.00 09/29/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353036
Principal investigator 1 ABBVIE INC. $12,024.00 09/04/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2, Multicenter, Platform Study of Targeted Therapies for the Treatment of Adult Subjects with Moderately to Severely Active Rheumatoid Arthritis No dispute reported 06/30/2026 1202509154
Principal investigator 1 ABBVIE INC. $2,115.00 09/04/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202509156
Principal investigator 1 Janssen Research & Development, LLC $712.00 09/01/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353073
Principal investigator 1 Eli Lilly and Company $213.45 08/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3 STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ORFORGLIPRON ONCE DAILY IN PARTICIPANTS WHO HAVE OBESITY OR OVERWEIGHT AND OSTEOARTHRITIS OF THE KNEE: A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PARALLEL-ARM, PLACEBO-CONTROLLED TRIAL No dispute reported 06/30/2026 1187877199
Principal investigator 1 Janssen Research & Development, LLC $1,726.00 08/11/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353107
Principal investigator 1 ABBVIE INC. $4,983.60 08/06/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Multicenter Randomized Study to Evaluate the Safety and Efficacy of Lutikizumab for Induction and Maintenance Therapy in Subjects with Moderately to Severely Active Ulcerative Colitis No dispute reported 06/30/2026 1202502390
Principal investigator 1 Eli Lilly and Company $11,329.00 07/23/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, CONTROLLED PRAGMATIC PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187886616
Principal investigator 1 Janssen Research & Development, LLC $1,968.00 07/07/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353090
Principal investigator 1 Novartis Pharmaceuticals Corporation $30,300.00 07/03/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190303069
Principal investigator 1 Eli Lilly and Company $266.61 06/24/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187887634
Principal investigator 1 Janssen Research & Development, LLC $2,916.00 06/02/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353065
Principal investigator 1 Eli Lilly and Company $11,050.00 05/27/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 4, PROSPECTIVE, OPEN-LABEL, SINGLE-ARM STUDY TO ASSESS THE EFFECTIVENESS OF TIRZEPATIDE AFTER INITIATION OF IXEKIZUMAB IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OVERWEIGHT OR OBESITY IN CLINICAL PRACTICE No dispute reported 06/30/2026 1187887636
Principal investigator 1 Janssen Research & Development, LLC $15,415.00 05/19/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175353015
Principal investigator 1 Eli Lilly and Company $15,251.00 05/12/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A MASTER PROTOCOL FOR A RANDOMIZED, PLACEBO-CONTROLLED CLINICAL TRIAL OF MULTIPLE INTERVENTIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS No dispute reported 06/30/2026 1187884696
Principal investigator 1 ABBVIE INC. $12,079.00 05/07/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2 Multicenter, Randomized, Platform Study of Advanced Therapies for the Treatment of Adult Subjects with Active Psoriatic Arthritis No dispute reported 06/30/2026 1202483415
Principal investigator 1 Janssen Research & Development, LLC $292.00 05/02/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175353022
Principal investigator 1 Janssen Research & Development, LLC $565.00 05/02/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A Phase 2a Multicenter, Randomized, Double Blind, Parallel, Proof of concept Study Evaluating the Efficacy and Safety of Nipocalimab and Certolizumab Combination Therapy in Participants with Active Rheumatoid Arthritis despite Prior Treatment with Advanc No dispute reported 06/30/2026 1175353082
Principal investigator 1 Novartis Pharmaceuticals Corporation $6,441.80 05/01/2025 Non-covered Recipient Entity
HOAG HOSPITAL
A Randomized, Double-blind, Parallel Group, Placebo-controlled Multicenter Study to Evaluate Efficacy, Safety and Tolerability of Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis No dispute reported 06/30/2026 1190302117
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $22,535.00 04/28/2025 Non-covered Recipient Entity
Christine Thai Md
A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) No dispute reported 06/30/2026 1235998148
Principal investigator 1 Janssen Research & Development, LLC $2,401.00 04/28/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353050
Principal investigator 1 Eli Lilly and Company $63,233.00 04/22/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187889226
Principal investigator 1 ABBVIE INC. $122.88 04/17/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202477678
Principal investigator 1 Janssen Research & Development, LLC $657.00 03/31/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353031
Principal investigator 1 ABBVIE INC. $2,125.00 03/26/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A Study Comparing Upadacitinib (ABT-494) to Placebo in Participants With Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Biologic Disease Modifying Anti-Rheumatic Drug (bDMARD) No dispute reported 06/30/2026 1202466122
Principal investigator 1 Eli Lilly and Company $3,329.89 03/25/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2A, SINGLE-ARM STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF LY3541860 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187886652
Principal investigator 1 Eli Lilly and Company $11,091.00 03/18/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187885932
Principal investigator 1 Eli Lilly and Company $65.40 03/10/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A RANDOMIZED, ACTIVE-CONTROLLED, PARALLEL-GROUP, PHASE 3B/4 STUDY OF BARICITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187884054
Principal investigator 1 Janssen Research & Development, LLC $2,680.00 03/03/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353043
Principal investigator 1 Eli Lilly and Company $1,965.53 02/25/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187886414
Principal investigator 1 Eli Lilly and Company $6,913.22 02/10/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187878285
Principal investigator 1 ABBVIE INC. $2,640.60 02/06/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
M23-784 - A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn s Disease No dispute reported 06/30/2026 1202447325
Principal investigator 1 Eli Lilly and Company $210.00 01/31/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187883402
Principal investigator 1 Eli Lilly and Company $6,081.01 01/27/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187882750
Principal investigator 1 Eli Lilly and Company $43.90 01/27/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187883400
Principal investigator 1 Eli Lilly and Company $5,398.33 01/27/2025 Non-covered Recipient Entity
THE OHIO STATE UNIVERSITY
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187892160
Principal investigator 1 Janssen Research & Development, LLC $1,968.00 01/27/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
Guselkumab in Active Psoriatic Arthritis Participants With Inadequate Response/Intolerance to One Prior Anti-TNF Alpha Agent No dispute reported 06/30/2026 1175353099
Principal investigator 1 Eli Lilly and Company $728.32 01/23/2025 Non-covered Recipient Entity
HOAG MEMORIAL HOSPITAL PRESBYTERIAN
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187882604
Principal investigator 1 Eli Lilly and Company $53.80 01/22/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187878643
Principal investigator 1 Eli Lilly and Company $256,031.00 01/21/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187876487
Principal investigator 1 Eli Lilly and Company $72,321.00 01/21/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
AN ADAPTIVE PHASE 2A/2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF LY3871801 IN ADULT PARTICIPANTS WITH MODERATELY-TO-SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187884694
Principal investigator 1 Eli Lilly and Company $12,094.00 01/21/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 3, MULTICENTER, OPEN LABEL, LONG TERM EXTENSION STUDY TO EVALUATE THE LONG TERM EFFICACY AND SAFETY OF MIRIKIZUMAB IN PATIENTS WITH CROHNS DISEASE No dispute reported 06/30/2026 1187886406
Principal investigator 1 Eli Lilly and Company $30,359.00 01/21/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
A PHASE 2B DOUBLE BLIND PLACEBO CONTROLLED STUDY TO EVALUATE PERESOLIMAB IN ADULT PARTICIPANTS WITH MODERATELY TO SEVERELY ACTIVE RHEUMATOID ARTHRITIS No dispute reported 06/30/2026 1187889224
Principal investigator 1 Eli Lilly and Company $43,290.00 01/13/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A STUDY OF REMTERNETUG VERSUS PLACEBO IN EARLY ALZHEIMER'S DISEASE PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE No dispute reported 06/30/2026 1187878971
Principal investigator 1 ABBVIE INC. $5,000.00 01/09/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202437598
Principal investigator 1 Eli Lilly and Company $2,606.30 01/09/2025 Non-covered Recipient Entity
VANCOUVER CLINIC INC PS
A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE No dispute reported 06/30/2026 1187893406
Principal investigator 1 ABBVIE INC. $50.00 01/08/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202437239
Principal investigator 1 ABBVIE INC. $50.00 01/08/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M15-572 - A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Participants With Psoriatic Arthritis Who Have an Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) No dispute reported 06/30/2026 1202437244
Principal investigator 1 Eli Lilly and Company $104,248.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187877279
Principal investigator 1 Eli Lilly and Company $427,643.00 01/07/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187877987
Principal investigator 1 Eli Lilly and Company $87,768.00 01/07/2025 Non-covered Recipient Entity
NEWPORT HUNTINGTON MEDICAL GROUP
EFFICACY AND SAFETY OF IXEKIZUMAB OR IXEKIZUMAB CONCOMITANTLY ADMINISTERED WITH TIRZEPATIDE IN ADULT PARTICIPANTS WITH ACTIVE PSORIATIC ARTHRITIS AND OBESITY OR OVERWEIGHT: A PHASE 3B, RANDOMIZED, MULTICENTER, OPEN-LABEL STUDY (TOGETHER-PSA) No dispute reported 06/30/2026 1187886614
Principal investigator 1 ABBVIE INC. $1,896.72 01/02/2025 Non-covered Recipient Entity
CARE ACCESS RESEARCH LLC
M15-998 - A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) No dispute reported 06/30/2026 1202433895